Lilly (LLY) CIO considers cloud for clinic data

Although Eli Lilly's ($LLY) use of cloud computing is primarily based on its drug discovery efforts now, the company has regulated drug development in its sites. But there are cloud business matters that need to be cleared up before that will happen, the company says, and they go beyond data security. 

CIO Michael Heim tells InformationWeek that the drug giant's right to audit, to know where in the cloud its data resides, and to know the provider's disaster recovery plans are chief among them. That's where the IT team is focusing as it tries to expand its use of the cloud.

Heim acknowledges that drug discovery presents an ideal work set for the cloud: lots of data, compute-intensive, long run times. "Often we want to take data that we have, marry it up with data that's publicly available--could be big genomic data sets--look at all of that collectively, and then extract value. So they're very bursty," he says in the article. A continuing challenge, however, is data transfers to and from the cloud.

- here's the article

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.